<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Oct. 20, 2020 (HealthDay News) — About one in three African American patients with chronic kidney disease (CKD) would be reclassified to a more severe CKD stage if the race classifier were removed from the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, according to a study published online Oct. 15 in the Journal of General Internal Medicine<\/i>.<\/p>\n
Salman Ahmed, M.D., M.P.H., from Brigham and Women’s Hospital in Boston, and colleagues examined the impact of the race multiplier for African Americans in the CKD-EPI estimated glomerular filtration rate (eGFR) equation on CKD classification and care delivery. Data were included for 2,225 African American patients in the Partners HealthCare System CKD Registry.<\/p>\n
The researchers found that if the race multiplier were removed from the CKD-EPI equation, 33.4 percent of the African American patients would hypothetically be reclassified to a more severe CKD stage; 24.3 percent would be reclassified from stage 3B to stage 4 and 3.1 percent would be reassigned from eGFR >20 to \u226420 mL\/min\/1.73 m\u00b2, meeting the criterion for accumulating kidney transplant priority. After the race multiplier was removed, 64 patients were reclassified from eGFR >20 to \u226420 mL\/min\/1.73 m\u00b2; none of these patients were referred, evaluated, or waitlisted for kidney transplant compared with 19.2 percent of African American patients with eGFR \u226420 mL\/min\/1.73 m\u00b2 using the default CKD-EPI equation.<\/p>\n
“Considering the inequities in kidney care and outcomes for Black patients, use of the eGFR race correction factor needs to be reconsidered,” a coauthor said in a statement.<\/p>\n
One author disclosed financial ties to the pharmaceutical industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n